NorthCrest Asset Manangement LLC Purchases 731 Shares of Zimmer Biomet Holdings, Inc. $ZBH

NorthCrest Asset Manangement LLC grew its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.3% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 57,964 shares of the medical equipment provider’s stock after buying an additional 731 shares during the quarter. NorthCrest Asset Manangement LLC’s holdings in Zimmer Biomet were worth $5,430,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently modified their holdings of ZBH. Ameriprise Financial Inc. lifted its holdings in shares of Zimmer Biomet by 236.0% during the 1st quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider’s stock valued at $517,039,000 after buying an additional 3,208,596 shares during the period. JPMorgan Chase & Co. increased its stake in shares of Zimmer Biomet by 251.3% in the 1st quarter. JPMorgan Chase & Co. now owns 2,081,381 shares of the medical equipment provider’s stock worth $235,571,000 after purchasing an additional 1,488,918 shares in the last quarter. Nuveen LLC purchased a new stake in shares of Zimmer Biomet in the 1st quarter worth $155,891,000. Alyeska Investment Group L.P. purchased a new stake in shares of Zimmer Biomet in the 1st quarter worth $101,294,000. Finally, Boston Trust Walden Corp purchased a new stake in shares of Zimmer Biomet in the 1st quarter worth $54,108,000. 88.89% of the stock is owned by institutional investors.

Insider Activity at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction on Monday, September 8th. The shares were sold at an average price of $104.15, for a total transaction of $156,225.00. Following the completion of the sale, the senior vice president directly owned 6,833 shares in the company, valued at approximately $711,656.95. The trade was a 18.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 1.39% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $100.15 on Friday. The firm has a market cap of $19.84 billion, a price-to-earnings ratio of 24.37, a PEG ratio of 2.30 and a beta of 0.68. The company’s 50 day moving average is $99.93 and its 200 day moving average is $99.46. The company has a quick ratio of 0.96, a current ratio of 1.87 and a debt-to-equity ratio of 0.54. Zimmer Biomet Holdings, Inc. has a 52-week low of $89.22 and a 52-week high of $114.72.

Zimmer Biomet (NYSE:ZBH) last issued its quarterly earnings data on Thursday, August 7th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.98 by $0.09. The company had revenue of $2.08 billion for the quarter, compared to analyst estimates of $2.06 billion. Zimmer Biomet had a net margin of 10.51% and a return on equity of 12.76%. Zimmer Biomet’s revenue was up 7.0% compared to the same quarter last year. During the same period last year, the company posted $2.01 earnings per share. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, sell-side analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. The ex-dividend date is Tuesday, September 30th. Zimmer Biomet’s payout ratio is presently 23.36%.

Analyst Ratings Changes

ZBH has been the subject of several analyst reports. Evercore ISI reduced their price objective on Zimmer Biomet from $102.00 to $96.00 and set an “in-line” rating for the company in a research note on Tuesday, July 8th. Royal Bank Of Canada increased their price target on Zimmer Biomet from $112.00 to $115.00 and gave the stock an “outperform” rating in a research note on Friday, August 8th. UBS Group increased their price target on Zimmer Biomet from $91.00 to $96.00 and gave the stock a “sell” rating in a research note on Friday, August 8th. Roth Capital reiterated a “buy” rating on shares of Zimmer Biomet in a research note on Thursday, August 7th. Finally, Rothschild & Co Redburn began coverage on shares of Zimmer Biomet in a report on Thursday. They set a “buy” rating and a $130.00 price objective for the company. Ten research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $112.06.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.